Benign Prostatic Hyperplasia Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Procedure (Transurethral Resection of the Prostate, Prostate Laser Surgery, Transurethral Microwave Thermotherapy, Transurethral Needle Ablation of the Prostate, Prostatic Urethral Lift, Water Vapor
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBenign Prostatic Hyperplasia Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Procedure (Transurethral Resection of the Prostate, Prostate Laser Surgery, Transurethral Microwave Thermotherapy, Transurethral Needle Ablation of the Prostate, Prostatic Urethral Lift, Water Vapor
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 11.09 Billion |
| CAGR (2023-2028) | 4.58% |
| Fastest Growing Segment | Minimal Invasive Surgery |
| Largest Market | North America |
Market Overview
Global Benign Prostatic Hyperplasia Treatment Devices Market
As the global population ages, the prevalence of BPH increases. With a rising number of elderly men, the demand for BPH treatment devices is on the rise, driving market growth.
The global market for Benign Prostatic Hyperplasia treatment devices is poised for substantial growth in the coming years. As the aging population continues to expand, technological innovations and growing awareness further bolster the demand for minimally invasive and effective BPH treatment options. Manufacturers, healthcare providers, and regulatory bodies need to work together to ensure that these technologies are accessible, safe, and efficient for patients worldwide. As we progress into an era of personalized medicine, the BPH treatment market is likely to witness more exciting advancements, improving the quality of life for those affected by this common condition.
Key Market Drivers
Increasing Aging Population is Driving the Global Benign Prostatic Hyperplasia Treatment Devices Market
According to the World Population Prospects 2019, by the United Nations, the number of people aged 60 and over is expected to more than double by 2050, reaching nearly 2.1 billion.
The increasing prevalence of BPH due to the aging population is a major driver for the global BPH treatment devices market. As more men experience the symptoms of BPH, the demand for effective treatment options continues to rise. BPH treatment devices offer a range of options, from minimally invasive procedures to surgical interventions, depending on the severity of the condition and the patient's preferences.
Rising Healthcare Expenditure in R&D is Driving the Global Benign Prostatic Hyperplasia Treatment Devices Market
The surge in healthcare expenditure is a crucial factor driving the growth of the BPH treatment devices market. The following are key ways in which increased healthcare spending is contributing to the expansion of the market.
Key Market Challenges
Regulatory Hurdles
One of the significant challenges in the BPH treatment devices market is navigating complex and varying regulatory landscapes across different regions. Each country has its own set of regulations and approval processes for medical devices. Manufacturers often need to undergo rigorous clinical trials and gain approvals from various regulatory bodies, such as the FDA in the United States and the European Medicines Agency (EMA) in Europe. The process can be time-consuming and expensive, posing obstacles for market entry. To overcome this challenge, companies in the BPH treatment devices market must invest in a thorough understanding of regional regulatory requirements. Collaborating with local experts and streamlining the approval process can help expedite market access.
Limited Awareness
Despite the prevalence of BPH, there is still a lack of awareness regarding the found at treatment options. Many patients and healthcare providers are unaware of the various minimally invasive treatment devices that can effectively manage BPH symptoms. This lack of awareness often leads to patients pursuing traditional treatments or delaying necessary interventions. Addressing the issue of limited awareness requires educational campaigns targeting both healthcare professionals and patients. Manufacturers should invest in marketing and educational initiatives to ensure that potential patients and their doctors are well-informed about the found at BPH treatment options.
Cost of Treatment
The cost of BPH treatment devices can be a significant barrier to patients seeking effective interventions. In many cases, these devices are not fully covered by health insurance, and the out-of-pocket expenses can be a concern for patients, particularly in countries with limited healthcare coverage. To tackle this challenge, manufacturers must consider pricing strategies that make these devices more accessible to a broader range of patients. This can involve working with healthcare providers and insurers to negotiate reimbursement agreements and exploring cost-effective manufacturing methods to reduce the overall price.
Competition in the Market
Evolving Technology
The field of medical devices is continuously evolving, with new technologies and treatment methods emerging. Staying at the forefront of these advancements is crucial for BPH treatment device manufacturers. Adopting the latest technology can be both a challenge and an opportunity, as it requires significant research and development efforts. Companies in the BPH treatment devices market should invest in research and development to stay up-to-date with the latest technologies. Collaboration with research institutions and healthcare providers can help identify and adapt to emerging trends.
Key Market Trends
Minimally Invasive Procedures on the Rise
One of the notable trends in the BPH treatment devices market is the growing preference for minimally invasive procedures. Traditionally, open surgery was the primary option for treating BPH. However, advancements in technology have given rise to minimally invasive procedures such as transurethral resection of the prostate (TURP), laser therapy, and transurethral microwave thermotherapy (TUMT). These procedures offer quicker recovery times, reduced hospital stays, and fewer complications, making them more attractive to patients
Adoption of Laser Therapy
Laser therapy has gained significant traction as an effective treatment for BPH. Laser devices, like the GreenLight laser and Holmium laser, are used to vaporize or remove excess prostate tissue. The appeal of laser therapy lies in its precision and minimal bleeding, making it a suitable option for patients taking blood-thinning medications or those with a higher risk of bleeding complications. The global BPH treatment devices market has seen a surge in the use of lasers, especially among urologists.
Innovative BPH Treatment Devices
Advancements in technology have led to the development of innovative BPH treatment devices. One such innovation is the UroLift System, which involves the placement of tiny implants to hold the enlarged prostate tissue out of the way. This procedure provides relief from BPH symptoms while preserving sexual function. Similarly, the Rezūm Water Vapor Therapy utilizes water vapor to treat BPH by shrinking the prostate tissue. These innovative approaches are contributing to the diversification of treatment options in the global market.
Increased Use of Robotic-Assisted Surgery
Robotic-assisted surgery, often associated with the da Vinci Surgical System, has been increasingly utilized in the treatment of BPH. This technology provides surgeons with enhanced precision and dexterity, resulting in reduced blood loss, shorter hospital stays, and quicker recovery times. Robotic-assisted procedures are becoming more accessible and are likely to become a standard in BPH treatment, especially in technologically advanced regions.
Growing Patient Awareness and Education
With the internet and social media at their fingertips, patients are becoming more informed about their healthcare options. This has led to increased patient awareness and education regarding BPH treatment devices. Patients are more likely to seek out non-invasive or minimally invasive procedures, and they often play an active role in selecting the best treatment option for themselves.
Expanding Geriatric Population
The global population is aging, and with that, the prevalence of BPH is expected to increase. This demographic shift is driving the demand for BPH treatment devices, creating a growing market for manufacturers. As a result, the market is likely to see a consistent upward trend in the coming years.
Advancements in Imaging and Diagnostics
Improvements in diagnostic tools, such as magnetic resonance imaging (MRI) and ultrasound, have enhanced the ability to accurately diagnose and evaluate the extent of BPH. This, in turn, enables more targeted and personalized treatment plans. As imaging technology continues to evolve, it will likely have a significant impact on BPH treatment device selection and surgical planning.
Segmental Insights
Treatment Insights
Based on the category of treatment, Minimal Invasive Surgery emerged as the dominant player in the global market for Benign Prostatic Hyperplasia Treatment Devices in 2022.
The UroLift system involves the placement of small implants that lift and hold the enlarged prostate tissue out of the way, effectively opening the urethra. This procedure offers rapid symptom improvement and preserves sexual function.
The surge in popularity of MIS in BPH treatment has had a significant impact on the global BPH treatment devices market. The market for devices used in MIS procedures, such as laser systems, resectoscopes, and implant systems, has grown substantially. Manufacturers have responded by developing innovative devices, enhancing precision, and improving patient outcomes. Furthermore, as patient awareness of these advanced treatment options increases, more individuals are opting for MIS procedures. This shift has fueled market growth, as patients seek the benefits of less invasive, more effective treatments.
Procedure Insights
The Transurethral Resection of the Prostate segment is projected to experience rapid growth during the forecast period. Transurethral Resection of the Prostate is a highly effective procedure for treating BPH, particularly in patients with moderate to severe symptoms or those experiencing complications like urinary retention. During Transurethral Resection of the Prostate, a surgeon trims away excess prostate tissue, relieving the pressure on the urethra and improving urine flow. The success rate of Transurethral Resection of the Prostate in relieving BPH symptoms is impressively high, making it a preferred choice among physicians and patients.
Download Free Sample Report
Regional Insights
North America emerged as the dominant player in the global Benign Prostatic Hyperplasia Treatment Devices market in 2022, holding the largest market share in terms of value. North America has been at the forefront of technological innovations in the medical field. The region boasts a thriving medical device industry, with companies consistently developing cutting-edge BPH treatment devices. These devices often utilize minimally invasive techniques, reducing recovery times and improving patient outcomes.
Recent Developments
- InMay 2023, Queen Margaret Hospital in Scotland made history by becoming thepioneer in providing advanced surgical therapy for an enlarged prostateutilizing the innovative iTind gadget. This novel technique entailed thetemporary insertion of a minuscule device into the prostate for a duration of 5to 7 days, followed by its complete removal. Once implanted, the iTind deviceundergoes expansion, applying gentle pressure, thereby reshaping the tissue atthe bladder's entrance and creating a broader pathway for the smooth passage ofurine.
- InMay 2022, the FDA in the United States granted approval for the RevoLix HTL, aHybrid Thulium laser treatment device produced by OmniGuide Holdings. Thisapproval was specifically for its use in urology procedures related to themanagement of kidney stones and benign prostatic hyperplasia (BPH) in patients.
Key Market Players
- Boston Scientific Corporation
- Olympus America
- EndoPharmaceuticals Inc.
- biolitec AG
- Medifocus Inc.
- Cook Medical
- TeleflexIncorporated
- Urotronic
- Coloplast Corp
- Richard WolfGmbH
- PROCEPT BioRoboticsCorporation
| By Treatment | By Procedure | By Product | By End use | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy